455 related articles for article (PubMed ID: 33759769)
1. Advanced Melanoma: Resistance Mechanisms to Current Therapies.
Haugh AM; Salama AKS; Johnson DB
Hematol Oncol Clin North Am; 2021 Feb; 35(1):111-128. PubMed ID: 33759769
[TBL] [Abstract][Full Text] [Related]
2. Combining BRAF/MEK Inhibitors with Immunotherapy in the Treatment of Metastatic Melanoma.
Ziogas DC; Konstantinou F; Bouros S; Theochari M; Gogas H
Am J Clin Dermatol; 2021 May; 22(3):301-314. PubMed ID: 33765322
[TBL] [Abstract][Full Text] [Related]
3. Mutant BRAF and MEK Inhibitors Regulate the Tumor Immune Microenvironment via Pyroptosis.
Erkes DA; Cai W; Sanchez IM; Purwin TJ; Rogers C; Field CO; Berger AC; Hartsough EJ; Rodeck U; Alnemri ES; Aplin AE
Cancer Discov; 2020 Feb; 10(2):254-269. PubMed ID: 31796433
[TBL] [Abstract][Full Text] [Related]
4. Cautious addition of targeted therapy to PD-1 inhibitors after initial progression of BRAF mutant metastatic melanoma on checkpoint inhibitor therapy.
Samlowski W; Adajar C
BMC Cancer; 2021 Nov; 21(1):1187. PubMed ID: 34743688
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms of Resistance to BRAF-Targeted Melanoma Therapies.
Dulgar O; Kutuk T; Eroglu Z
Am J Clin Dermatol; 2021 Jan; 22(1):1-10. PubMed ID: 33368052
[TBL] [Abstract][Full Text] [Related]
6. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
7. Immune Responses to BRAF-Targeted Therapy in Melanoma: Is Targeted Therapy Immunotherapy?
Kelley MC
Crit Rev Oncog; 2016; 21(1-2):83-91. PubMed ID: 27481005
[TBL] [Abstract][Full Text] [Related]
8. Immunomodulatory Effects of BRAF, MEK, and CDK4/6 Inhibitors: Implications for Combining Targeted Therapy and Immune Checkpoint Blockade for the Treatment of Melanoma.
Lelliott EJ; McArthur GA; Oliaro J; Sheppard KE
Front Immunol; 2021; 12():661737. PubMed ID: 34025662
[TBL] [Abstract][Full Text] [Related]
9. Combinatorial Approaches to the Treatment of Advanced Melanoma.
Munhoz RR; Postow MA
Hematol Oncol Clin North Am; 2021 Feb; 35(1):145-158. PubMed ID: 33759771
[TBL] [Abstract][Full Text] [Related]
10. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition.
Amaral T; Sinnberg T; Meier F; Krepler C; Levesque M; Niessner H; Garbe C
Eur J Cancer; 2017 Mar; 73():93-101. PubMed ID: 28162869
[TBL] [Abstract][Full Text] [Related]
11. Drug resistance of BRAF-mutant melanoma: Review of up-to-date mechanisms of action and promising targeted agents.
Rossi A; Roberto M; Panebianco M; Botticelli A; Mazzuca F; Marchetti P
Eur J Pharmacol; 2019 Nov; 862():172621. PubMed ID: 31446019
[TBL] [Abstract][Full Text] [Related]
12. Tumor microenvironment changes leading to resistance of immune checkpoint inhibitors in metastatic melanoma and strategies to overcome resistance.
Pulluri B; Kumar A; Shaheen M; Jeter J; Sundararajan S
Pharmacol Res; 2017 Sep; 123():95-102. PubMed ID: 28690075
[TBL] [Abstract][Full Text] [Related]
13. Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Yu C; Liu X; Yang J; Zhang M; Jin H; Ma X; Shi H
Front Immunol; 2019; 10():990. PubMed ID: 31134073
[TBL] [Abstract][Full Text] [Related]
14. Outcomes after progression of disease with anti-PD-1/PD-L1 therapy for patients with advanced melanoma.
Patrinely JR; Baker LX; Davis EJ; Song H; Ye F; Johnson DB
Cancer; 2020 Aug; 126(15):3448-3455. PubMed ID: 32463489
[TBL] [Abstract][Full Text] [Related]
15. Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation.
Kiniwa Y; Nakamura K; Mikoshiba A; Ashida A; Akiyama Y; Morimoto A; Okuyama R
BMC Cancer; 2021 Mar; 21(1):287. PubMed ID: 33731038
[TBL] [Abstract][Full Text] [Related]
16. Resistance to combination BRAF and MEK inhibition in metastatic melanoma: Where to next?
Welsh SJ; Rizos H; Scolyer RA; Long GV
Eur J Cancer; 2016 Jul; 62():76-85. PubMed ID: 27232329
[TBL] [Abstract][Full Text] [Related]
17. An observational study of drug utilization and associated outcomes among adult patients diagnosed with BRAF-mutant advanced melanoma treated with first-line anti-PD-1 monotherapies or BRAF/MEK inhibitors in a community-based oncology setting.
Cowey CL; Boyd M; Aguilar KM; Beeks A; Krepler C; Scherrer E
Cancer Med; 2020 Nov; 9(21):7863-7878. PubMed ID: 32871054
[TBL] [Abstract][Full Text] [Related]
18. Systemic Therapy Options for Patients With Unresectable Melanoma.
Yushak M; Chapman P; Robert C; Kudchadkar R
Am Soc Clin Oncol Educ Book; 2017; 37():661-672. PubMed ID: 28561662
[TBL] [Abstract][Full Text] [Related]
19. Treatment Options for Advanced Melanoma After Anti-PD-1 Therapy.
Babacan NA; Eroglu Z
Curr Oncol Rep; 2020 Mar; 22(4):38. PubMed ID: 32198651
[TBL] [Abstract][Full Text] [Related]
20. Recent advances in molecular targeted therapy for unresectable and metastatic BRAF-mutated melanoma.
Kiniwa Y; Okuyama R
Jpn J Clin Oncol; 2021 Mar; 51(3):315-320. PubMed ID: 33338202
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
